Clinical Trials · NCT06584006
Thymalfasin and Recombinant Human IL-2 Injections in Treating Lymphocytopenia for Patients With Malignant Hematological Tumors
- Phase
- Phase 2
- Recruitment status
- Recruiting
- Sponsor
- The First Affiliated Hospital of Xiamen University
- Enrollment
- 50
- Start date
- Sep 2024
- Locations
- 1 site, China
- Primary endpoint
- Lymphocyte count and its subgroup count